Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 15, 2016

Bayer announces Phase III CHICO study of Nifurtimox to treat Chagas disease

Bayer has announced a Phase III CHICO study of Nifurtimox to treat children of all age groups with Chagas disease.

Bayer has announced a Phase III CHICO study of Nifurtimox to treat children of all age groups with Chagas disease.

Nifurtimox is a newly developed medicine by Bayer and is enlisted as one of the 'Essential Medicines' by the World Health Organisation for both adults and children.

Chagas is an infectious disease caused by single-cell parasites (trypanosoma), which spreads through the faeces / urine of kissing bugs or triatomines.

It can also be transmitted by infected blood transfusions, organ transplantation, or during pregnancy / birth from the infected mother to her unborn child.

The Chagas disease in children treated with nifurtimox (CHICO) study will be conducted as a prospective, historically controlled study to test the efficacy, safety and pharmacokinetics of Nifurtimox for the treatment of children with Chagas disease.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
"As the manufacturer of Nifurtimox, we have a long-term commitment to the fight against this disease."

The study will enrol 390 pediatric patients, including newborn babies.

Bayer pharmaceuticals division president and member of the board of management Dieter Weinand said: "As the manufacturer of Nifurtimox, we have a long-term commitment to the fight against this disease.

"Children are the most vulnerable patient group. Every child who can be treated is a step toward getting the disease under control."

The two-arm study will have a 30-day and 60-day treatment cycles against historical untreated control and intends to determine an appropriate, weight-adjusted dose of Nifurtimox for newborns and children using fast-disintegrating 30mg and 120mg tablets, which will be divided among weight-adjusted dosing in all age groups.


Image: Photomicrograph of Trypanosoma cruzi. Photo: courtesy of Dr. Myron G. Schultz.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU